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ABSTRACT  
BACKGROUND: Aspirin use is associated with reduced risk of several cancers. A 
pooled analysis of 12 case-control studies showed a 10% decrease in ovarian cancer 
risk with regular aspirin use, which was stronger for daily and low dose users. To 
prospectively investigate associations of analgesic use with ovarian cancer, we 
analyzed data from 13 studies in the Ovarian Cancer Cohort Consortium (OC3). 
METHODS: The current study included 758,829 women who at study enrollment self-
reported analgesic use, among whom 3,514 developed ovarian cancer. Using Cox 
regression, we assessed associations between frequent medication use and risk of 
ovarian cancer. Dose and duration were also evaluated. All statistical tests were two-
sided.  
RESULTS: Women who used aspirin almost daily (≥6 days/week) vs. infrequent/non-
use experienced a 10% reduction in ovarian cancer risk [rate ratio (95% confidence 
interval): 0.90 (0.82 -1.00), p=0.05]. Frequent use (≥4 days/week) of aspirin [0.95 (0.88-
1.03)], non-aspirin NSAIDs [1.00 (0.90-1.11)], or acetaminophen [1.05 (0.88-1.24)] was 
not associated with risk. Daily acetaminophen use [1.28 (1.00-1.65), p=0.05] was 
associated with elevated ovarian cancer risk. Risk estimates for frequent, long-term 
(10+ years) use of aspirin [1.15 (0.98-1.34)] or non-aspirin NSAIDs [1.19 (0.84-1.68)] 
were modestly elevated, although not statistically significant.  
CONCLUSIONS: This large, prospective analysis suggests that women who use aspirin 
daily have a slightly lower risk of developing ovarian cancer (~10% lower than 
infrequent/non-use)—similar to the risk reduction observed in case-control analyses. 
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The observed potential elevated risks for 10+ years of frequent aspirin and NSAID use 
require further study, but could be due to confounding by medical indications for use or 
variation in drug dosing.  
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INTRODUCTION  
Ovarian cancer is the most fatal gynecologic cancer, largely due to delayed symptom 
presentation and lack of early detection strategies. Chemoprevention has not been 
widely studied but may present approaches to reduce ovarian cancer burden. Chronic 
inflammation likely plays a key role in ovarian carcinogenesis (1). Factors associated 
with epithelial disruption through ovulation (2, 3), inflammation-related exposures such 
as endometriosis and pelvic inflammatory disease (4, 5), and circulating biomarkers of 
inflammation (6, 7) have been associated with ovarian cancer risk. 
Inhibition of cyclooxygenase (COX) enzymes in prostaglandin synthesis is a 
primary mechanism responsible for the anti-inflammatory and anti-neoplastic effects of 
nonsteroidal anti-inflammatory drugs (NSAIDs) (8, 9), and may play a role in ovarian 
carcinogenesis. Additionally, NSAIDs may suppress ovulation and affect cell 
proliferation, angiogenesis, and apoptosis of the epithelium(10). Acetaminophen, 
another common analgesic and antipyretic, has weak anti-inflammatory activity and 
anti-gonadotropic effects (11). It also may inhibit ovarian carcinogenesis through the 
depletion of glutathione leading to necrosis (12). Aspirin, non-aspirin NSAIDs, and 
acetaminophen are widely used, so any increased or decreased cancer risk may have 
important public health implications. 
Cardiovascular disease prevention trials have shown that daily aspirin use is 
associated with reduced risk and mortality of several malignancies (e.g., colorectal 
cancer) (13). However, the limited number of women in these trials are insufficient to 
evaluate ovarian cancer endpoints (14).  
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A recent pooled analysis of 12 case-control studies in the Ovarian Cancer 
Association Consortium (OCAC) reported a reduced risk of ovarian cancer with aspirin 
use, particularly for daily aspirin users (15). High-dose non-aspirin NSAID use, but not 
acetaminophen, was also associated with lower risk (15). The few prospective 
observational studies between aspirin or other NSAID use and ovarian cancer risk have 
had inconsistent results (16-20). Prospective studies avoid potential biases that may 
occur in case-control studies, including differences between non-responders and 
responders among cases or controls or differences in recollection or reporting of 
medication use after being diagnosed with ovarian cancer. However, the decreased risk 
observed for aspirin or non-aspirin NSAIDs and the lack of association with 
acetaminophen in case-control studies argues against substantial differential recall (15). 
Further, the exposure window being evaluated in case-control studies is often shortly 
before cancer diagnosis, during which use may be influenced by preclinical disease. 
Prospective assessment of analgesic use many years before ovarian cancer diagnosis 
is necessary to confirm the association with an eye toward improving prevention 
recommendations. Thus, we evaluated the association between frequent aspirin, non-
aspirin NSAID, and acetaminophen use with ovarian cancer risk using prospective 
individual-level data from the Ovarian Cancer Cohort Consortium (OC3).  
 
METHODS 
Study population 
The study population included women participating in 16 prospective cohort studies 
from North America and Europe (Supplementary Table 1; (16, 17, 19, 21-35)). Eligible 
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studies were a cohort study or clinical trial with prospective follow-up including women, 
determination of ovarian cancer endpoints through questionnaire/medical record follow-
up or confirmation by cancer registries, and follow-up for death. This analysis was 
limited to 13 studies that collected information on frequent aspirin, non-aspirin NSAID, 
or acetaminophen (paracetamol) use over at least a 6-month period (n=758,829). All 
studies obtained institutional approval at their respective institution(s); participants 
provided either written informed consent or implicit consent through return of the study 
questionnaire. The OC3 Data Coordinating Center and analytic approaches were 
approved by the institutional review board of the Brigham and Women’s Hospital.  
 
Exposure definitions 
Medication use was self-reported at enrollment (Supplementary Table 1; (16, 17, 19, 
21, 22, 24-27, 29-34)). Given the rationale for assessment of frequent use based on 
biologic mechanisms and published research (13-15), we focused on frequent 
medication use (at least 4-5 days/week) when possible. Frequency was available in ten 
of 13 studies (16, 17, 21, 24, 25, 29-32); while three studies included frequency in their 
definition of regular medication use (19, 22, 26). Frequent use was defined as use at 
least 4-5 times per week for at least 6 months duration; less frequent use or non-regular 
use/no use were combined to form the reference group. We also evaluated very 
frequent (daily/almost daily) use for at least 6 months duration as one of the following: 
6-7 days/week, 7 days/week, or ≥28 days per month (11 studies; (16, 17, 21, 22, 24, 25, 
29-32)). Frequency variables were further divided by duration of use (all medications; 
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≥0.5-5, >5-10, >10 years, 9 studies (16, 19, 24-26, 30-32)) and aspirin dose (<100 (or 
“baby aspirin”) and ≥100 mg; 4 studies (16, 19, 23, 31)).  
Potential confounding variables were harmonized from the studies as part of a 
core dataset. A priori adjustment factors included: baseline age (continuous), body 
mass index (<20, 20-24.9, 25-29.9, 30-34.9, ≥35 kg/m2), number of births (0, 1, 2, 3, ≥4 
full-term births), duration of oral contraceptive (OC) use (never, ≤1, >1-5, >5-10, >10 
years), and menopause/duration of menopausal hormone therapy (premenopausal, 
postmenopausal: never, ≤5, >5-10, >10 years).  
 
Outcome definitions 
We included epithelial ovarian or peritoneal tumors identified either through cancer 
registries or medical record review (ICD9 codes 183 and 158; ICD10 codes C56). We 
first evaluated associations of medications with all tumors combined (ovarian and 
peritoneal; n=3,514). Second, we evaluated associations for invasive epithelial ovarian 
cancers (n=3,147) and third, evaluated associations for the four most common tumor 
histotypes: serous (n=1,475, including tumors coded as poorly differentiated), 
endometrioid (n=233), mucinous (n=125), and clear cell (n=111). The remaining 1,203 
cases had another histology (e.g., mixed) or were missing histology information (n=817) 
and were censored at diagnosis date in histology-specific analyses.  
 
Statistical methods 
Women were excluded from primary analyses if they had a history of cancer (other than 
non-melanoma skin cancer) at baseline, bilateral oophorectomy prior to study entry, or 
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were missing age. We calculated hazard ratios (HR) and 95% confidence intervals 
(95% CI) using Cox proportional hazards regression to evaluate the association 
between the analgesic medications and risk of ovarian cancer. Women entered the 
analysis at age at study entry and contributed person-time until the age at first diagnosis 
of ovarian cancer (event), death (censored), or end of follow-up (censored), whichever 
came first. In primary analyses, we pooled data from all cohorts, stratifying on cohort to 
account for potential differences in baseline hazards. Secondarily, we used meta-
analysis of cohort-specific estimates to assess between-study heterogeneity. 
Associations between analgesic medication use and ovarian cancer histotype were 
calculated using competing-risks Cox regression (36). Statistical heterogeneity of 
associations across histotypes was assessed via likelihood ratio test comparing a model 
that assumed different associations for the exposure of interest by histotype (full model) 
to a model with a single estimate across histotypes (reduced model) (37).  
Effect modification by factors that influence inflammation (e.g., smoking, BMI, 
history of chronic disease) and established ovarian cancer risk factors (e.g., age, parity, 
OC use, endometriosis) was evaluated using multiplicative interaction terms, with 
significance assess by a likelihood ratio test.  
In sensitivity analyses, we considered a common reference group, coding “non-
frequent users” as women who reported no or infrequent use of aspirin, non-aspirin 
NSAIDs, and acetaminophen to account for analgesic usage patterns. We also 
excluded women who reported a history of chronic disease at baseline to assess 
potential indication for medication use and explored the potential for reverse causation 
by evaluating associations of frequent analgesic use with ovarian cancer cases that 
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occurred <5 years, 5-<10 years, and ≥10 years after baseline. Another sensitivity 
analysis considered death as a competing risk (rather than censoring). Exposure curves 
from survivor function plots were parallel suggesting no deviation from proportional 
hazards. All statistical tests were two-sided, and p-values<0.05 were considered 
statistically significant; analyses were performed using SAS 9.1. 
 
RESULTS 
Study characteristics 
The proportion of women reporting frequent analgesic use increased with age; for 
example, among women reporting frequent aspirin use, 17.7% were <50 years, while 
52.2% were 60 years of age or older (Table 1). Compared to women who did not use 
aspirin or who used it infrequently, women who frequently used aspirin were more likely 
to be older, postmenopausal, have a history of a chronic disease, have higher BMI, and 
were less likely to have previously used OCs. Average follow-up after exposure 
assessment was 10.8 years (maximum 18.9); individual cohort follow-up is reported in 
Supplementary Table 1. 
 
Aspirin 
Women who used aspirin at least 4-5 times per week (n=851 exposed cases [events]) 
developed ovarian cancer at about the same rate as women who did not use or used 
only infrequently [HR (95% CI): 0.95 (0.88-1.03)] (Table 2). However, compared to 
infrequent/non-users, women reporting daily or almost daily use (at least 6 days/week or 
more; n=449 cases) had a 10% reduction in ovarian cancer risk [0.90 (0.82-1.00), 
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p=0.05]. This association was statistically significant for women reporting daily or almost 
daily use for 0.5-<5 years in duration [0.79 (0.63-0.99), p=0.04; n=87 cases], and 
suggestively associated for daily users for 5-10 years duration [0.88 (0.65-1.18), n=50 
cases]. Conversely, women who frequently used (vs. infrequent/non-use) aspirin for 
long durations (≥10 years at baseline) had a non-statistically significant elevated risk of 
ovarian cancer [1.15 (0.98-1.34), p=0.09; n=212 cases]. No associations were observed 
when analyzing aspirin dose or other patterns of duration. In analyses by histotype 
(Table 3), results for serous ovarian cancers were similar to those seen for all ovarian 
cancer: compared to infrequent/non-use, daily aspirin use was associated with a 15% 
decrease for serous tumors [95% CI: 0.71-1.00; n=159 cases], whereas 10 or more 
years of frequent aspirin use was related to a suggestively elevated risk [1.27 (0.99-
1.62); n=74 cases]. A similar pattern was observed for clear cell tumors; however, risk 
estimates were imprecise due to limited numbers. No associations were observed for 
endometrioid or mucinous tumors. 
 
Non-aspirin NSAID 
Women who frequently used non-aspirin NSAIDs had a similar rate of ovarian cancer as 
infrequent/non-users [1.00 (0.90-1.11); n=426 cases] (Table 2). Longer duration or daily 
frequency of non-aspirin NSAID was not related to ovarian cancer risk, although the risk 
estimate for ovarian cancer for frequent, long duration (≥10 years) use of non-aspirin 
NSAID was suggestively elevated [1.19 (0.84-1.68), n=36 cases)]. In analyses by 
histotype, women who frequently used (vs. infrequent/non-use) non-aspirin NSAIDs for 
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long durations had an increased risk of serous tumors than women who used it 
infrequently or not at all [2.06 (1.14-3.74); n=10 cases] (Table 3).  
 
Acetaminophen 
Frequent use compared to infrequent/non-use of acetaminophen was not associated 
with ovarian cancer risk [1.05 (0.88-1.24); n=152 exposed cases] (Table 2). However, 
there was a suggestive elevated risk with daily acetaminophen use [1.28 (1.00-1.65), 
p=0.05; n=71 cases] that was stronger for serous tumors [1.70 (1.14-2.55); n=26 cases] 
(Table 3).  
 
Additional analyses 
There was little heterogeneity across studies (data not shown). Risk estimates were 
generally similar across age strata (Supplementary Table 2). Compared to 
infrequent/non-users, daily aspirin use was related to reduced ovarian cancer risk 
among women <50 [0.89 (0.43-1.84)], 50-59 [0.92 (0.73-1.17)], and 60-69 [0.88 (0.75-
1.04)] years old at baseline, but was null for women ≥70 years old [1.05 (0.82-1.36), p-
interaction=0.73]. Daily acetaminophen use was only associated with increased ovarian 
cancer risk among women ≥70 years old [1.78 (1.17-2.72), p-interaction<0.001]. Results 
were similar across strata of other ovarian cancer risk factors (data not shown). 
Results were similar in analyses restricted to invasive ovarian cancers, utilizing a 
common reference group, and accounting for death as a competing risk (data not 
shown). In analyses excluding women with a history of chronic disease, elevated risk 
estimates with frequent longer duration use of aspirin or non-aspirin NSAIDs were 
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attenuated [aspirin: 1.11 (0.93-1.33); non-aspirin NSAIDs: 1.04 (0.68-1.60)], other 
associations, including for acetaminophen, remained unchanged. Associations were 
slightly stronger for frequent long duration use of aspirin or daily acetaminophen use for 
cases diagnosed within 5 years of baseline compared to ≥5 years after baseline (data 
not shown). 
 
DISCUSSION 
We observed a 10% reduced ovarian cancer risk for daily aspirin use although only for 
women who had used aspirin for less than 10 years; use for 10+ years was associated 
with a null or slightly elevated risk. Non-aspirin NSAID and acetaminophen use was not 
clearly related to ovarian cancer risk overall; however, we observed an increased risk 
for very frequent (daily/almost daily for at least six months) acetaminophen use. Further, 
like aspirin, long duration, frequent non-aspirin NSAID use was associated, at least 
suggestively, with elevated risk of ovarian cancer. The modest reduced risk for daily 
aspirin use is consistent with previous observations from case-control studies (15), 
although the suggestively elevated risk with long duration of frequent analgesic use 
requires further evaluation.  
Importantly, in this analysis, we were able to evaluate patterns of duration to 
characterize a dose-response association; however, unlike colorectal cancer, in which 
longer duration of use is associated with further risk reductions (38), the reduced risk of 
ovarian cancer with frequent aspirin use was only apparent with short to moderate 
duration (the largest exposure stratum) and appeared null or slightly elevated with 
longer duration use (≥10 years). This may be because those who frequently used 
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aspirin for many years may be more likely to use standard versus low-dose aspirin. That 
said, availability of data on very long durations of use was limited, as evidenced by the 
less precise estimates in this group. A better understanding of the relationship between 
frequency and duration of use leveraging updated exposure data is needed to assess 
potential causality of the daily aspirin-ovarian cancer relationship, including 
ascertainment of use during potentially critical time periods given that the increased risk 
for long-duration use was strongest for cases diagnosed early in follow-up. Further, 
consideration of associations for daily aspirin use and its timing/duration with ovarian 
cancer is needed to fully assess potential for primary prevention, particularly given the 
relatively low prevalence of ovarian cancer as well as risk related adverse events (e.g. 
upper gastrointestinal bleeding). Consistent with our results, pooled analyses of clinical 
trial data demonstrate that daily aspirin use is most relevant for risk reduction of 
colorectal cancer and cancer risk overall (39), as alternate dosing trials (higher dose or 
every other day use) did not show clear benefits (40).  
The previous pooled case-control study and our current study support that daily 
aspirin use is associated with lower ovarian cancer risk. The weaker association in the 
prospective studies versus case-control studies is similar to results for breast cancer 
risk (14). Although recall bias may lead to a stronger association in case-control studies, 
we would expect this to attenuate any true reductions in risk with daily aspirin use. 
Alternately, considering analgesic use collected at study entry may lead to 
misclassification of exposure status over follow-up (which averaged over a decade long) 
that could attenuate results. Conversely, we observed a consistently elevated ovarian 
cancer risk with frequent, long duration use of aspirin and non-aspirin NSAIDs, 
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suggesting potential confounding by medical indications for long-term use. We could not 
directly address this since indication for use was not collected in most studies. To 
address in sensitivity analyses, we excluded women who reported a history of chronic 
disease at baseline and observed some attenuation in risk estimates. That said, further 
assessment of confounding by medical indications for long-term use, such as joint pain, 
osteoarthritis, cardiovascular disease, or other factors is needed, as well as 
consideration of potential biologic mechanisms by which long-term use may increase 
risk.  
Consistent with our results, acetaminophen use was not associated with ovarian 
cancer risk in the pooled case-control study data (15), based on more than 400 exposed 
cases (odds ratio for daily vs. non-regular use: 0.95 (0.74-1.23)). Acetaminophen and 
non-aspirin NSAIDs are commonly used interchangeably; however acetaminophen has 
only weak anti-inflammatory properties, and may have gonadotrophic effects (11), 
supporting the different associations we observed between NSAIDs and acetaminophen 
in our study and suggesting different anti-inflammatory effects or other mechanisms of 
action (8, 9, 11). Importantly, the increased risk with daily acetaminophen use observed 
in this study was based on a limited number of exposed cases and should be 
interpreted with caution. 
The consistent positive relationship for frequent long duration use of aspirin or 
non-aspirin NSAIDs with serous disease, may suggest that long-term users likely have 
other factors that increase inflammation and thus risk of this histotype. Some data 
suggest that serous tumors may be more strongly related to inflammatory factors. For 
example, aggressive high grade serous tumors have been more commonly associated 
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with inducible nitric oxide synthase and other inflammatory markers than low grade 
tumors.(41) Further, pre-diagnostic circulating inflammatory marker, C-reactive protein, 
has been associated with the serous histotype (6, 42). Lifetime ovulations also were 
more strongly associated with tumors expressing p53 (43), a hallmark of serous disease 
(44).  
The prospective design of the pooled studies precludes recall bias. Additional 
strengths of the study include the large sample size, the ability to identify deaths as well 
as capture loss to follow-up, and the ability to account for many known and suspected 
risk factors for ovarian cancer. Limitations included the use of self-reported exposure 
data, limited information on low-dose aspirin use, and limited data on health conditions 
or medical indications underlying long-term analgesic use. The combination of long-term 
follow-up and ascertainment of exposure at baseline (in most studies) meant that 
individuals could have started or stopped use during follow-up, which would contribute 
to measurement error. Further, information on duration of use at baseline may not 
adequately represent exposure duration, as such confounding by indication may not 
fully explain the elevated risks. Residual confounding by age-related factors may also 
be present; however, we did not observe substantial differences in associations across 
age-strata.  
The incidence of ovarian cancer is low; thus our modest findings are unlikely to 
alter the balance of more common and clinically significant risks and benefits associated 
with daily aspirin use. However, the associations stratified by age at baseline provide 
information relevant to current United States Preventive Services Taskforce (USPSTF) 
recommendations regarding aspirin use for cardiovascular-prevention (45), as 
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decreased ovarian cancer risk estimates associated with daily aspirin use were only 
observed among women <70 years old. The USPSTF does not recommend frequent 
aspirin use in women ≥70 years because of increased risks for adverse events. While 
the potential increased risk associated with daily acetaminophen as well as frequent 
aspirin and non-aspirin NSAID use for more than 10 years duration requires further 
study, daily aspirin use may provide a very modest reduced risk with respect to incident 
ovarian cancer. 
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Table 1. Distribution of frequent analgesic use by baseline demographic and health characteristics in the 
Ovarian Cancer Cohort Consortium (OC3), n=758,829 
Characteristics 
Aspirin non-aspirin NSAID Acetaminophen 
Infrequent/                 
non-use 
Frequent*  
use 
Infrequent/                 
non-use 
Frequent* 
use 
Infrequent/                 
non-use 
Frequent*  
use 
n % n % n % n % n % n % 
Age mean (SD) 54.7 (11.4) 59.4 (10.1) 59.1 (9.5) 59.6 (8.5) 57.7 (10.6) 60.9 (10.0) 
Age (years) 
              <50 171,049 31.0 28,462 17.7 68,208 15.8 10,496 12.9 69,762 22.9 3,973 14.4 
  50-59 182,326 33.0 48,432 30.1 144,873 33.6 29,425 36.1 101,553 33.4 8,351 30.3 
  60+ 198,689 36.0 84,044 52.2 218,295 50.6 41,609 51.0 132,697 43.6 15,244 55.3 
BMI (kg/m2) 
              <20 38,712 7.0 9,460 5.9 28,981 6.7 3,239 4.0 20,937 6.9 1,513 5.5 
  20-24.9 246,476 44.6 63,791 39.6 183,064 42.4 25,614 31.4 127,806 42.0 9,216 33.4 
  25-29.9 157,968 28.6 49,716 30.9 130,232 30.2 25,969 31.9 89,960 29.6 8,560 31.1 
  30-34.9 61,441 11.1 21,816 13.6 51,919 12.0 14,072 17.3 36,797 12.1 4,342 15.8 
  35+ 33,201 6.0 12,620 7.8 26,604 6.2 10,813 13.3 21,015 6.9 3,068 11.1 
   Missing  14,266 2.6 3,535 2.2 10,576 2.5 1,823 2.2 7,497 2.5 869 3.2 
Age at menarche (years) 
              ≤11 129,521 23.5 39,029 24.3 104,278 24.2 22,428 27.5 58,358 19.2 5,549 20.1 
   12 132,550 24.0 43,314 26.9 107,177 24.8 22,151 27.2 82,000 27.0 8,085 29.3 
   13 155,896 28.2 42,510 26.4 122,489 28.4 19,967 24.5 87,684 28.8 6,628 24.0 
   14 71,928 13.0 21,378 13.3 55,615 12.9 10,314 12.7 44,990 14.8 4,640 16.8 
   ≥15 48,479 8.8 13,304 8.3 38,367 8.9 6,361 7.8 27,904 9.2 2,428 8.8 
   Missing  13,690 2.5 1,403 0.9 3,450 0.8 309 0.4 3,076 1.0 238 0.9 
Duration, oral contraceptive use (years) 
          Never 210,399 38.1 79,036 49.1 193,635 44.9 32,992 40.5 112,760 37.1 11,756 42.6 
   >0-1  43,208 7.8 14,589 9.1 32,672 7.6 7,606 9.3 27,743 9.1 2,557 9.3 
   >1-5  97,165 17.6 24,065 15.0 67,121 15.6 13,458 16.5 47,757 15.7 3,612 13.1 
   >5-10  78,116 14.1 16,254 10.1 48,201 11.2 9,520 11.7 36,471 12.0 2,323 8.4 
   >10  104,143 18.9 24,316 15.1 76,349 17.7 16,530 20.3 65,839 21.7 6,257 22.7 
   Missing  19,033 3.4 2,678 1.7 13,398 3.1 1,424 1.7 13,442 4.4 1,063 3.9 
Number pregnancies 
          0 85,920 15.6 16,579 10.3 56,916 13.2 9,977 12.2 42,630 14.0 2,899 10.5 
   1 60,572 11.0 14,426 9.0 45,993 10.7 8,030 9.8 35,178 11.6 2,988 10.8 
   2 177,064 32.1 44,857 27.9 128,389 29.8 23,169 28.4 97,780 32.2 7,997 29.0 
   3 131,053 23.7 42,162 26.2 110,188 25.5 21,291 26.1 67,767 22.3 6,372 23.1 
   4+ 93,130 16.9 41,287 25.7 85,208 19.8 17,992 22.1 55,969 18.4 6,706 24.3 
   Missing  4,325 0.8 1,627 1.0 4,682 1.1 1,071 1.3 4,688 1.5 606 2.2 
Menopausal status 
           Premenopausal 188,738 34.2 31,168 19.4 83,184 19.3 12,792 15.7 82,248 27.1 3,986 14.5 
   Postmenopausal 348,494 63.1 125,619 78.1 342,938 79.5 67,335 82.6 216,731 71.3 22,957 83.3 
   Missing  14,832 2.7 4,151 2.6 5,254 1.2 1,403 1.7 5,033 1.7 625 2.3 
Age at menopause (years) among postmenopausal women 
      39-45 45,905 12.6 15,523 12.0 45,476 13.1 8,341 12.1 33,314 15.0 3,162 13.4 
   46-50 89,057 24.5 32,661 25.2 86,398 24.8 15,875 23.1 60,363 27.2 6,024 25.5 
   51-55 123,290 33.9 43,577 33.6 125,242 36.0 22,357 32.5 77,772 35.1 7,313 31.0 
   >55 24,452 6.7 9,294 7.2 25,889 7.4 5,503 8.0 14,587 6.6 1,600 6.8 
   Missing  80,622 22.2 28,715 22.1 65,187 18.7 16,662 24.2 35,728 16.1 5,483 23.3 
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Duration, menopausal hormone use (years) 
            Never 273,921 49.6 73,279 45.5 165,228 38.3 26,744 32.8 112,911 37.1 9,282 33.7 
   >0-5  78,836 14.3 29,980 18.6 73,431 17.0 16,284 20.0 54,914 18.1 6,446 23.4 
   >5-10  43,492 7.9 16,040 10.0 41,755 9.7 9,652 11.8 30,399 10.0 3,512 12.7 
   >10  42,380 7.7 20,700 12.9 44,658 10.4 13,673 16.8 28,174 9.3 4,487 16.3 
   Missing  113,435 20.5 20,939 13.0 106,304 24.6 15,177 18.6 77,614 25.5 3,841 13.9 
History of chronic diseases a baseline included:         
Any cardiovascular disease 
           No 19,146 3.5 11,630 7.2 22,121 5.1 8,655 10.6 26,078 8.6 4,698 17.0 
   Yes 1,763 0.3 1,545 1.0 2,500 0.6 808 1.0 2,859 0.9 449 1.6 
   Missing  531,155 96.2 147,763 91.8 406,755 94.3 72,067 88.4 275,075 90.5 22,421 81.3 
Diabetes 
               No 440,316 85.2 113,913 82.0 308,678 79.5 55,152 81.8 200,184 72.8 14,468 64.5 
   Yes 15,142 2.9 9,472 6.8 16,115 4.2 4,131 6.1 9,268 3.4 1,500 6.7 
   Missing  61,381 11.9 15,541 11.2 63,500 16.4 8,161 12.1 65,623 23.9 6,453 28.8 
Autoimmune disease 
            No 86,690 18.2 35,539 25.5 104,565 28.7 20,401 31.8 115,614 49.5 9,414 49.4 
   Yes 6,192 1.3 4,179 3.0 7,292 2.0 3,159 4.9 9,630 4.1 1,855 9.7 
   Missing  383,645 80.5 99,626 71.5 252,748 69.3 40,667 63.3 108,156 46.3 7,787 40.9 
 
*Frequent: use at least ~4-5 days/week for 6 months or longer. BMI, body mass index; NSAID, 
nonsteroidal anti-inflammatory drugs; SD, standard deviation.  
29 
 
Table 2.  Associations between analgesic use and ovarian cancer risk in the Ovarian Cancer Cohort 
Consortium (OC3), n=758,829 
 
Analgesic use 
 N 
events 
(cases)  
 Person-
years  HR* (95% CI) P† 
Aspirin     
Infrequent/non-use  2404 4,946,886 1.00 ref  
Frequent use‡ 851 1,408,656 0.95 (0.88-1.03) 0.23 
Frequent use by duration vs. infrequent/non-use 
infrequent/non-use  1402 3,150,285 1.00 ref  
frequent/0.5-<5 years 239 504,116 0.92 (0.80-1.06) 0.24 
frequent/5-<10 years 93 171,582 0.90 (0.72-1.12) 0.33 
frequent/10+ years 212 305,987 1.15 (0.98-1.34) 0.09 
Categories of frequent use vs. infrequent/non-use 
infrequent/non-use  1936 3,245,903 1.00 ref  
<daily use 156 161,238 1.06 (0.90-1.26) 0.49 
 daily use§ 449 545,499 0.90 (0.82-1.00) 0.05 
Categories of frequent use by duration vs. infrequent/non-use 
infrequent/non-use  1402 3,150,285 1.00 ref  
<daily/0.5-<5 years 152 379,640 1.02 (0.85-1.21) 0.87 
<daily/5-<10 years 43 108,355 0.92 (0.67-1.26) 0.60 
<daily/10+ years 113 260,503 1.12 (0.92-1.37) 0.26 
daily/0.5-<5 years 87 124,476 0.79 (0.63-0.99) 0.04 
daily/5-10 years 50 63,227 0.88 (0.65-1.18) 0.39 
daily/10+ years 99 45,484 1.18 (0.93-1.50) 0.18 
Frequent use by dose vs. infrequent/non-use 
infrequent/non-use  392 436,742 1.00 ref  
frequent low dose 115 72,719 0.99 (0.79-1.23) 0.91 
frequent normal dose 144 130,684 0.94 (0.77-1.15) 0.55 
Non-aspirin NSAID 
   Infrequent/non-use  2305 3,798,980 1.00 ref  
Frequent use‡ 426 614,745 1.00 (0.90-1.11) 0.96 
Frequent use by duration vs. infrequent/non-use 
infrequent/non-use  1168 2,051,666 1.00 ref  
frequent/0.5-<5 years 122 237,614 0.94 (0.78-1.14) 0.54 
frequent/5-<10 years 64 75,230 1.10 (0.85-1.42) 0.49 
frequent/10+ years 36 29,429 1.19 (0.84-1.68) 0.33 
Categories of frequent use vs. infrequent/non-use 
infrequent/non-use  1982 3,049,045 1.00 ref  
<daily use 104 124,937 1.07 (0.88-1.31) 0.50 
daily use§ 237 319,625 0.97 (0.84-1.11) 0.65 
Categories of frequent use vs. infrequent/non-use 
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infrequent/non-use  1168 2,051,666 1.00 ref  
<daily/0.5-<5 years 83 159,749 1.02 (0.81-1.28) 0.88 
<daily/5-<10 years 39 43,940 1.31 (0.95-1.81) 0.10 
<daily/10+ years 15 18,356 1.10 (0.66-1.84) 0.72 
daily/0.5-<5 years 39 77,865 0.81 (0.58-1.14) 0.23 
daily/5-<10 years 25 31,290 0.86 (0.57-1.30) 0.48 
daily/10+ years 21 11,074 1.27 (0.80-2.01) 0.32 
Acetaminophen 
    Infrequent/non-use  1421 2,583,452 1.00 ref  
Frequent use‡ 152 213,668 1.05 (0.88-1.24) 0.61 
Frequent use by duration vs. infrequent/non-use 
infrequent/non-use  1386 2,425,711 1.00 ref  
frequent/0.5-<5 years 61 95,060 0.99 (0.76-1.29) 0.93 
frequent/5-<10 years 50 50,683 1.16 (0.87-1.54) 0.32 
frequent/10+ years 37 51,266 1.01 (0.73-1.41) 0.96 
Categories of frequent use vs. infrequent/non-use 
infrequent/non-use  1179 2,120,248 1.00 ref  
<daily use 35 43,645 0.99 (0.70-1.39) 0.94 
daily use§ 71 62,759 1.28 (1.00-1.65) 0.05 
Categories of frequent use by duration vs. infrequent/non-use 
infrequent/non-use  1386 2,425,711 1.00 ref  
<daily/0.5-<5 years 33 69,923 0.87 (0.62-1.22) 0.42 
<daily/5-<10 years 25 35,311 0.98 (0.66-1.46) 0.93 
<daily/10+ years 22 39,950 0.89 (0.58-1.36) 0.58 
daily/0.5-<5 years 28 25,137 1.21 (0.81-1.81) 0.35 
daily/5-<10 years 25 15,372 1.42 (0.94-2.13) 0.09 
daily/10+ years 15 11,315 1.24 (0.75-2.08) 0.40 
* Hazard ratios (HR) and 95% confidence intervals (CI) are estimated from Cox proportional hazards 
models stratified on study cohort and adjusted for baseline age (continuous), body mass index (<20, 20-
24.9, 25-29.9, 30-34.9, ≥35 kg/m2), number of births (none, one, two, three, four or more full-term births), 
duration of oral contraceptive (OC) use (never, ≤1, >1-5, >5-10, >10 years), and duration of menopausal 
hormone therapy (MHT) use (premenopausal, never, ≤5, >5-10, >10 years). 
† P value calculated using a two-sided Wald test 
‡Frequent: use at least ~4-5 days/week for 6 months or longer 
§Daily: use at least ~6-7 days/week or ≥28 days per month for 6 months or longer 
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Table 3. Associations between analgesic use and ovarian carcinoma histologic subtypes, Ovarian Cancer Cohort Consortium (OC3). 
Analgesic use P het* 
Serous (n=1,470) Endometrioid (n=233) Mucinous (n=125) Clear Cell (n=111) 
N 
events HR† (95% CI) 
N 
events HR† (95% CI) 
N 
events HR† (95% CI) 
N 
events HR† (95% CI) 
Aspirin          
Infrequent/non-use  0.26 1141 1.00 ref 181 1.00 ref 93 1.00 ref 85 1.00 ref 
Frequent use‡  307 0.93 (0.81-1.05) 45 0.90 (0.64-1.27) 29 1.13 (0.73-1.75) 25 1.11 (0.71-1.74) 
Frequent use by duration vs. infrequent/non-use 
 infrequent/non-use 0.03 680 1.00 ref 132 1.00 ref 52 1.00 ref 59 1.00 ref 
 frequent/0.5-<5 years  69 0.85 (0.73-0.99) 18 0.93 (0.62-1.40) 10 1.03 (0.60-1.74) 5 0.75 (0.40-1.42) 
 frequent/5-<10 years  37 0.89 (0.64-1.24) 8 1.28 (0.62-2.66) 2 0.67 (0.16-2.87) 4 1.46 (0.52-4.12) 
 frequent/10+ years  74 1.27 (0.99-1.62) 8 0.64 (0.31-1.31) 10 1.69 (0.83-3.42) 10 1.97 (0.98-3.97) 
Categories of frequent use vs. infrequent/non-use 
 infrequent/non-use 0.13 938 1.00 ref 139 1.00 ref 62 1.00 ref 67 1.00 ref 
 <daily use  57 1.04 (0.86-1.25) 3 0.86 (0.55-1.34) 1 0.93 (0.53-1.63) 4 1.35 (0.75-2.41) 
 daily use§  159 0.85 (0.71-1.00) 20 0.95 (0.59-1.54) 14 1.40 (0.77-2.56) 9 0.87 (0.44-1.73) 
Non-aspirin NSAID           
Infrequent/non-use  0.06 984 1.00 ref 139 1.00 ref 67 1.00 ref 75 1.00 ref 
Frequent use‡  157 1.09 (0.92-1.30) 18 1.03 (0.61-1.73) 8 0.86 (0.41-1.77) 6 0.53 (0.23-1.22) 
Frequent use by duration vs. infrequent/non-use 
 infrequent/non-use 0.03 456 1.00 ref 71 1.00 ref 31 1.00 ref 47 1.00 ref 
 frequent/0.5-<5 years  38 1.01 (0.83-1.23) 7 1.09 (0.63-1.89) 2 0.84 (0.38-1.86) 2 0.54 (0.22-1.34) 
 frequent/5-<10 years  20 1.39 (0.87-2.22) 2 1.04 (0.25-4.31) 1 1.51 (0.20-11.63) 1 0.71 (0.10-4.95) 
 frequent/10+ years  10 2.06 (1.14-3.74) 0 -- 0 -- 0 -- 
Categories of frequent use vs. infrequent/non-use 
 infrequent/non-use 0.04 883 1.00 ref 115 1.00 ref 61 1.00 ref 69 1.00 ref 
 <daily use  38 1.15 (0.87-1.53) 7 1.36 (0.61-3.00) 3 1.65 (0.65-4.20) 1 0.45 (0.11-1.83) 
   daily use§  102 1.06 (0.86-1.31) 9 0.87 (0.45-1.67) 3 0.49 (0.15-1.58) 4 0.58 (0.21-1.59) 
Acetaminophen 
 
 
  
 
 
 
 
 
 Infrequent/non-use  0.21 577 1.00 ref 103 1.00 ref 38 1.00 ref 50 1.00 ref 
Frequent use‡  47 1.29 (0.94-1.77) 11 1.77 (0.96-3.29) 2 0.70 (0.16-2.99) 4 1.49 (0.43-5.17) 
Frequent use by duration vs. infrequent/non-use 
 infrequent/non-use 0.01 557 1.00 ref 100 1.00 ref 38 1.00 ref 46 1.00 ref 
 frequent/0.5-<5 years  22 1.36 (0.87-2.12) 3 0.72 (0.20-2.64) 0 -- 3 2.42 (0.57-10.35) 
 frequent/5-<10 years  15 1.44 (0.85-2.43) 5 3.66 (1.54-8.69) 1 1.68 (0.23-12.17) 1 1.48 (0.18-11.91) 
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 frequent/10+ years  8 0.97 (0.48-1.96) 3 1.92 (0.58-6.32) 1 1.30 (0.16-10.48) 0 -- 
Categories of frequent use vs. infrequent/non-use 
 infrequent/non-use 0.09 554 1.00 ref 102 1.00 ref 35 1.00 ref 46 1.00 ref 
 <daily use  9 0.95 (0.60-1.51) 1 1.70 (0.78-3.69) 1 1.15 (0.22-6.03) 3 1.69 (0.33-8.59) 
   daily use§  26 1.70 (1.14-2.55) 6 1.85 (0.75-4.57) 0 -- 1 1.15 (0.17-8.01) 
*The P value for heterogeneity (P het) was calculated using a two-sided likelihood ratio test. [37, Gates et al. 2010] 
†Hazard ratios (HR) and 95% confidence intervals (CI) are estimated from competing risk [Gates et al. citation] Cox proportional hazards models 
stratified on study cohort and adjusted for baseline age (continuous), body mass index (<20, 20-24.9, 25-29.9, 30-34.9, ≥35 kg/m2), number of 
births (none, one, two, three, four or more full-term births), duration of oral contraceptive (OC) use (never, ≤1, >1-5, >5-10, >10 years), and 
duration of menopausal hormone therapy (MHT) use (premenopausal, never, ≤5, >5-10, >10 years). Competing risk models were based on fixed 
covariate effects; variable covariate effect results were practically identical (data not shown). 
‡ Frequent; use at least ~4-5 days/week for 6 months or longer 
§Daily: use at least ~6-7 days/week or ≥28 days per month for 6 months or longer 
 
